SCHEMBL24254271

SCHEMBL24254271

Cc1ccc(S(=O)(=O)n2cncn2)s1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.49
POLB P06746 2/20 0.40
MEN1 O00255 2/20 0.35
LMNA P02545 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
PKM P14618 2/20 0.35
TP53 P04637 2/20 0.35
S1PR4 O95977 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35
ALOX15 P16050 1/20 0.35
S1PR1 P21453 1/20 0.35
HTT P42858 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
KIT P10721 2/20 0.33
BRD4 O60885 1/20 0.33
CREBBP Q92793 1/20 0.33
NAMPT P43490 1/20 0.31
CYP19A1 P11511 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24254268 0.81 TSHR (0.47) KMT2APOLBMEN1LMNASMN1; SMN2
SCHEMBL24254270 0.81 L3MBTL1 (0.43) KMT2AMEN1LMNASMN1; SMN2ALDH1A1
SCHEMBL24254288 0.74 POLB (0.58) KMT2APOLBMEN1LMNASMN1; SMN2
SCHEMBL24254285 0.72 PKM (0.59) KMT2APOLBLMNAPKMALDH1A1
SCHEMBL24254277 0.67 KMT2A (0.56) KMT2APOLBMEN1LMNASMN1; SMN2
SCHEMBL24254273 0.66 MAPT (0.50) KMT2APOLBMEN1LMNASMN1; SMN2
SCHEMBL14049745 0.66 KMT2A (1.00) KMT2APOLBMEN1LMNASMN1; SMN2
SCHEMBL2606680 0.64 KMT2A (0.52) KMT2APOLBMEN1LMNASMN1; SMN2
SCHEMBL12195521 0.63 SMN1; SMN2 (0.38) POLBSMN1; SMN2ALDH1A1S1PR1HTT
SCHEMBL16732 0.63 KMT2A (0.50) KMT2APOLBMEN1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230257373-A1 QUORUM SENSING INHIBITORS AND METHODS OF USE NATIONAL INSTITUTES OF HEALTH 2023-08-17 US claimed
EP-4196108-A1 QUORUM SENSING INHIBITORS AND METHODS OF USE The Trustees of Indiana University (US) 2023-06-21 EP claimed
WO-2022036282-A1 QUORUM SENSING INHIBITORS AND METHODS OF USE THE TRUSTEES OF INDIANA UNIVERSITY (US) 2022-02-17 WO claimed
US-20230257373-A1 QUORUM SENSING INHIBITORS AND METHODS OF USE NATIONAL INSTITUTES OF HEALTH 2023-08-17 US disclosed
US-20230257373-A1 QUORUM SENSING INHIBITORS AND METHODS OF USE NATIONAL INSTITUTES OF HEALTH 2023-08-17 US disclosed
US-20230257373-A1 QUORUM SENSING INHIBITORS AND METHODS OF USE NATIONAL INSTITUTES OF HEALTH 2023-08-17 US disclosed
EP-4196108-A1 QUORUM SENSING INHIBITORS AND METHODS OF USE The Trustees of Indiana University (US) 2023-06-21 EP disclosed
WO-2022036282-A1 QUORUM SENSING INHIBITORS AND METHODS OF USE THE TRUSTEES OF INDIANA UNIVERSITY (US) 2022-02-17 WO disclosed
WO-2022036282-A1 QUORUM SENSING INHIBITORS AND METHODS OF USE THE TRUSTEES OF INDIANA UNIVERSITY (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257373-A1 QUORUM SENSING INHIBITORS AND METHODS OF USE PGLS, BLVRB, CGAS KMT2A 4067/4885POLB 3399/4885MEN1 3392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.